BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• BioMidwest

  Ludwig Enterprises Announces Effectiveness of Form S-1 Registration Application, Becomes an SEC Reporting Company

  Ludwig Enterprises, Inc. announced that the U.S. Securities and Exchange Commission has declared the Company’s Registration Statement on Form S-1 effective as of November 8, 2023.

  November 14, 2023

   · 

  3 min read
• Business

  SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

  SAB Biotherapeutics, Inc. today reported financial results for the third quarter ended October 31, 2023, and provided a company update.

  November 14, 2023

   · 

  9 min read
• Drug Development

  IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson’s DiseasePhase 2 MONTPARK trial expected to begin recruiting patients in Q1 2024

  IntelGenx Corp. announced that the Swedish Medical Products Agency, the Swedish Ethical Review Authority, and the Regional Biobank Centre have approved the planned clinical study to investigate the use of IntelGenx’s Montelukast VersaFilm® for the treatment of Parkinson’s Disease.

  November 14, 2023

   · 

  5 min read
• SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

  SAB Biotherapeutics, Inc. today announced the funding of the second tranche of a previously-announced financing, raising total aggregate proceeds to date of $67.1 million.

  November 14, 2023

   · 

  6 min read
• Business

  DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  DMK Pharmaceuticals Corporation today announced financial results for the third quarter ended September 30, 2023, and provided an update on recent corporate developments.

  November 14, 2023

   · 

  12 min read
• Business

  Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

  Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023.

  November 14, 2023

   · 

  9 min read
• Business

  Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

  Entera Bio Ltd. today reported corporate updates and financial results for the third quarter ended September 30th, 2023.

  November 14, 2023

   · 

  14 min read
• Business

  CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

  CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update.

  November 14, 2023

   · 

  17 min read
• CytoMed Therapeutics to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

  CytoMed Therapeutics Limited today announced it will be presenting at The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7th, 2023 at the New York Athletic Club in New York City.

  November 14, 2023

   · 

  2 min read
• BioMidwest

  Inspire Medical Systems, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference

  Inspire Medical Systems, Inc. announced that its management team will present at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023.

  November 14, 2023

   · 

  1 min read